期刊文献+

2008—2010年北京市房山区良乡医院口服非甾体抗炎药应用分析

Utilization of Non-steroidal Anti-inflammatory Drugs in Beijing Fangshan District Liangxiang Hospital During 2008-2010
下载PDF
导出
摘要 目的:了解我院口服非甾体抗炎药(NSAID)的应用情况,为临床合理应用NSAID提供参考。方法:对2008—2010年我院口服NSAID的用药频度(DDDs)、销售金额、限定日费用(DDC)进行统计分析。结果:2008—2010年,我院DDDs、销售金额排序居前3位的口服NSAID分别为阿司匹林、萘丁美酮和美洛昔康。DDC最低的口服NSAID是阿司匹林,为0.52元;最高的是塞来昔布,为14.93元。结论:我院口服NSAID使用基本合理。 OBJECTIVE:To investigate the utilization of non-steroidal anti-inflammatory drugs(NSAIDs) in Beijing Fangshan District Liangxiang Hospital for clinical references of rational use of NSAIDs.METHODS: The utilization of NSAIDs in Beijing Fangshan District Liangxiang Hospital during 2008-2010 was analyzed with regard to DDDs,consumption sum and defined daily cost(DDC).RESULTS: During 2008-2010,aspirin,nabumetone and meloxicam ranked the top 3 places in our hospital in terms of DDDs and consumption sum.In terms of DDC,oral NSAIDs ranked the last place at 0.52 Yuan while celecoxib the first place at 14.93 Yuan.CONCLUSION: The utilization structure of non-steroidal anti-inflammatory drugs in our hospital was rational on the whole.
作者 李霞 吕世臣
出处 《中国医院用药评价与分析》 2012年第12期1073-1075,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 非甾体抗炎药 用药频度 销售金额 限定日费用 应用分析 Non-steroidal anti-inflammatory drugs DDDs Consumption sum Defined daily cost Utilization analysis
  • 相关文献

参考文献7

二级参考文献29

  • 1哈力,哈娜,胡宝荣.塞来昔布安全性与耐受性评价[J].中国药师,2005,8(4):323-324. 被引量:6
  • 2杨景勋.万络事件及COX-2抑制剂心血管安全性的最新评估[J].药物不良反应杂志,2005,7(2):150-154. 被引量:18
  • 3龚培力,杨晓燕,曾繁典,傅鹰.非甾体抗炎药存在的安全性问题——FDA的声明及各国的反应[J].药物流行病学杂志,2005,14(3):172-175. 被引量:10
  • 4Sheng H,J Clin Invest,1997年,99卷,2254页
  • 5Philadelphia, PA. Penn Study Points to New Evidence to Explain How COX-2 Inhibitors Can Eventually Lead to Heart Disease and Stroke [ EB/OL]. http://www, uphs. upenn.edu/ news/ News_Releases/ mayO5 / prostacyclin, htm , 2005-04-24.
  • 6Hermann M, Camici G, Fratton A, Hurlimann D. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension [ J ]. Circulation, 2003,108:2308-2311.
  • 7Mason KP, Ruschitzka F, Simon LS, et al. The Pulse ofCurrent Cardiovascular Concern: Anti-inflammatory Medications [ EB/OL ]. http ://www. medscape, com/viewprogram/3690_pnt, 2004-02-22.
  • 8Topoi EJ. Failing the public heahh-rofecoxib, Merck, and the FDA[J]. N Engl J of Med, 2004,351:1707-1709.
  • 9Mukherjee D, Nissen SE, Topoi EJ , et al. Risk of cardiovascular events associated with selective COX-2 inhibitors [ J ] . JAMA, 2001,286:954-959.
  • 10Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [ J ]. N Engl J Med, 2005 , 352 ( 11 ) :1092-1102.

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部